ULTRAGENYX PHARMACEUTICAL INC. Business Acquisition, Pro Forma Net Income (Loss)
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Business Acquisition, Pro Forma Net Income (Loss) of $341.70 million for the 12-month period ending 2017-12-31, per its 10-K filed 2020-02-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2020-02-14
- ULTRAGENYX PHARMACEUTICAL INC. business acquisition, pro forma net income (loss) for fiscal 2017 was $341.70M, a 11.45% increase from fiscal 2016.
- ULTRAGENYX PHARMACEUTICAL INC. business acquisition, pro forma net income (loss) for fiscal 2016 was $306.60M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 12 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month as first filed |
|---|---|---|
| 2017-12-31 | $341.70M 10-K · filed 2020-02-14 | $341.74M 10-K · filed 2018-02-21 |
| 2016-12-31 | $306.60M 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |